Objectives: To compare prostate cancer detection rates in repeated biopsy depending on the number of cores at initial biopsy. Methods: Out of 3,000 consecutive patients, 534 underwent repeat extended biopsies. At first procedure, 345 patients had undergone standard biopsies (10–15 cores; SBx) whereas 189 other patients had already had a 21-core extended protocol (ExtBx). Clinicobiological and pathological parameters were compared between 2 groups. Results: The prostate cancer detection rate was significantly higher in the SBx group (37%) compared with the ExtBx group (16.8%, p < 0.001). Mean PSA level, mean percent free PSA and mean prostate volume were equivalent in both groups. Thirty-eight percent of cancers detected in the SBx group were graded Gleason 7 or more, compared with 19.3% in the ExtBx group (p = 0.018). Mean percent of core invasion was 25.3% in the SBx group compared to 15.9% in the ExtBx group (p = 0.004). Conclusions: A full evaluation of all prostate zones using ExtBx seems to be necessary to decrease the risk of undetected prostate cancer on repeated biopsies. For patients who had at their first biopsy an ExtBx, the risk of prostate cancer on the repeated biopsies and the risk of aggressive cancer were lower compared to standard biopsies.

Keywords:
Detection rate, Prostate cancer, Repeat biopsy, Saturation biopsy
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.